Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

IOX4

  Cat. No.:  DC10825   Featured
Chemical Structure
1154097-71-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM).
Cas No.: 1154097-71-8
Chemical Name: Tert-butyl 6-(5-oxo-4-(1H-1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinate
Synonyms: IOX4 NEW;IOX4;tert-butyl 6-(5-oxo-4-(1H-1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinate;BDBM118338;ZB1530;US8653111, 62;tert-butyl 6-[3-oxo-4-(triazol-1-yl)-1H-pyrazol-2-yl]pyridine-3-carboxylate
SMILES: O(C(C1=C([H])N=C(C([H])=C1[H])N1C(C(=C([H])N1[H])N1C([H])=C([H])N=N1)=O)=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
Formula: C15H16N6O3
M.Wt: 328.3259
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC50 value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2[1].
In Vitro: IOX4 (1-100 μM; 5 hours) determines the EC50s for HIF1α induction are 114 μM, 86 μM and 49.5 μM in MCF-7, Hep3B and U2OS, respectively[1].
References: [1]. Chan MC, et al. Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain. PLoS One. 2015 Jul 6;10(7):e0132004.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10339 Vadadustat Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.
DC7486 PX-478 2HCL PX-478 is an inhibitor of HIF-1a with an IC50 of 20-30μM enhances radiosensitivity of prostate carcinoma cells.
DC10464 PT2385 PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity.
DC8390 Oltipraz Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3.
DC12043 KHS-101 KHS101 is a selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 μM).
DC8447 KC7F2 KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
DC8617 JNJ-42041935 JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.
DC10825 IOX4 IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM).
DC8166 Molidustat(BAY 85-3934) Hypoxia-inducible factor prolyl hydroxylase inhibitor
DC5193 Roxadustat(FG-4592) FG-4592 is an HIF αprolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production.
X